Adverum Biotechnologies Reports Progress in Gene Therapy for Ocular Diseases
For individuals and families navigating the challenges of inherited retinal diseases (IRDs) and other prevalent ocular conditions, advancements in gene therapy offer a beacon of hope. Adverum Biotechnologies, a clinical-stage company focused on gene therapy for eye diseases, recently released its financial results for the fourth quarter and full year 2024, alongside updates on its pipeline. While their primary focus is currently on wet age-related macular degeneration (wet AMD), their work in gene therapy platforms holds broader implications for the future treatment of various retinal conditions.
Adverum Biotechnologies is pioneering the use of gene therapy to preserve sight, aiming to establish it as a new standard of care for highly prevalent ocular diseases. The company is developing durable, single-administration therapies designed to be delivered in physicians' offices, potentially eliminating the need for frequent ocular injections. Their lead clinical-stage gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022), is being developed for the treatment of wet AMD. This therapy utilizes a proprietary vector capsid, AAV.7m8, to deliver an aflibercept coding sequence.
Recent reports indicate that patients in their OPTIC clinical trial continued to experience long-term benefits from Ixo-vec through at least four years of follow-up. These benefits included maintenance of vision, durability of anatomical improvements, and a sustained reduction in anti-VEGF treatment burden. Stable aflibercept levels have been demonstrated for as long as measured, up to five years post-treatment. The 2E11 dose of Ixo-vec was generally well tolerated and showed a favorable safety profile. Furthermore, long-term data from the OPTIC trial established a 10-fold safety margin from the highest dose tested in wet AMD to the 6E10 dose selected for Phase 3.
For patients and their families, these developments highlight the potential for a transformative treatment approach. Current standard-of-care treatments for wet AMD often require frequent injections, which can be a significant burden. A one-time gene therapy, if successful, could offer long-term vision preservation and significantly reduce the need for repeated procedures, improving quality of life. Adverum's CEO, Laurent Fischer, M.D., stated that Ixo-vec is